Renal Cancer Drug Pipeline Update 2008

The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being less than 20% (RCC) in this patient cohort.The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets.

There are today more than 160 therapeutics targeting renal cancer, from early preclinical to marketed drugs. Renal Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 131 different targets. TThese targets are further categorized on the CD-ROM by 42 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Renal Cancer Drug Pipeline Update is organized.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

* Find competitors, collaborations partners, M&A candidates etc.

* Jump start competitive drug intelligence operations

* Excellent starting point for world wide benchmarking

* Compare portfolio and therapy focus with your peers

* Speed up pro-active in-/out licensing strategy work

* Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.

Drug Pipeline Update is delivered to you as a CD-ROM application, which requires no installation on your computer. Please read more about application features and system requirements - hot more..

May 2008
More...
Price: $2,350.00 / GBP1,175.00